Correlation between brain natriuretic peptide levels and the prognosis of patients with left ventricular diastolic

Hui Gong1, Xin Wang2, Yi-Jun Shi2

  • 1Department of Internal Medicine, Division of Cardiology, Huashan Hospital of Fudan University, Shanghai 200040, P.R. China.

Insights

Elevated brain natriuretic peptide (BNP) levels indicate a worse prognosis in cardiovascular disease patients with left ventricular diastolic dysfunction. Higher BNP levels correlate with increased mortality and shorter survival times, suggesting BNP as a predictive biomarker.

Area of Science:

  • Cardiology
  • Biomarkers
  • Prognostic Indicators

Background:

  • Left ventricular (LV) diastolic dysfunction is a common complication in cardiovascular disease.
  • Brain natriuretic peptide (BNP) is a hormone released in response to cardiac stress.
  • The prognostic value of BNP in patients with LV diastolic dysfunction requires further investigation.

Purpose of the Study:

  • To investigate the association between brain natriuretic peptide (BNP) levels and prognosis in patients with left ventricular (LV) diastolic dysfunction.
  • To determine if BNP can serve as a predictive biomarker for cardiovascular disease outcomes.

Main Methods:

  • A cohort of 708 cardiovascular disease inpatients was analyzed.
  • Patients were grouped based on initial BNP levels (≤80 pg/ml vs. >80 pg/ml).
  • Follow-up occurred for 20-51 months, with endpoints including mortality and cardiovascular readmission. Echocardiography was performed on 677 patients.

Main Results:

  • Patients with BNP >80 pg/ml had a significantly higher endpoint occurrence rate (26.28% vs. 16.14%) and shorter survival durations.
  • A significant negative correlation between BNP levels and survival time was found in patients with LV diastolic dysfunction (E/A≤1).
  • No significant correlation was observed in patients with normal LV diastolic function (E/A>1).

Conclusions:

  • Elevated BNP levels are associated with a worse prognosis in cardiovascular disease patients.
  • BNP levels demonstrate significant predictive value for prognosis specifically in patients with LV diastolic dysfunction.
  • BNP may serve as a valuable biomarker for predicting outcomes in this patient population.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
717
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K